NDEWS was first funded by the National Institute on Drug Abuse (NIDA) in 2014 to expand the longstanding Community Epidemiology Workgroup (CEWG). In April 2020, the second iteration of the NIDA-funded NDEWS was awarded to our team from the University of Florida, New York University, and Florida Atlantic University. NDEWS…
NDEWS Co-Investigator Dr. Bruce Goldberger and NDEWS Scientific Advisory Group Member Dr. Barry Logan, along with other collaborators at NMS Labs and the Center for Forensic Science Research and Education, recently published an article on the synthetic cathinone eutylone (bk-EBDB), which was identified in 83 forensic investigations from thirteen states.
NDEWS Principal Investigator Dr. Linda B. Cottler, co-editor of Addictive Disorders for Current Opinion in Psychiatry, invited articles in the July 2020 issue on new psychoactive substances (NPS) and approaches to drug monitoring, including a description of the NDEWS effort from our predecessors at the University of Maryland.
NDEWS Co-Investigator Dr. Joseph Palamar discusses the re-emergence of gamma-hydroxybutyric acid (GHB) with NBC News in a new article.
Dr. Nora Volkow, the Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health, describes the NDEWS COVID-19 supplement in her blog post. Read more about our initiative to track substance-use-related COVID-19 consequences through local key informant interviews in all 18 sentinel sites.
This press release from UF Health provides an overview of the new National Drug Early Warning System (NDEWS), funded to UF by the National Institute on Drug Abuse (NIDA) in April 2020.